Acute cerebral and peripheral circulation disorders.
The main characteristic of the present therapeutic strategy in acute cerebral ischemias, peripheral occlusive arterial disease, hyperviscosity, hypovolemic and other shock syndromes is the rapid counteraction on the underlying regional and general microcirculation insufficiency by administration of Dextrans (40 and 60 or 70 respectively) causing increase of reduced (micro)flow and metabolism, antithrombotic effects and volume replacement. Including the respectively needed precaution and concomiting therapy (stabilization of B. P., heart and metabolism disorders, electrolyte correction, analgetics, antibiotics etc.) the chances for improvement or reversibility of the pathophysiological and clinical dysfunctions and for rehabilitation can be elevated by these conceptions. Dextran 60 (70) is superior to blood and gelatine in intensity and keeping volume replacement (until to 25-30% of lossed volume), in microcirculatory and hemodilution potency and with regard to risks and economic aspects. The use of these programs is very successful also in geriatrics.
D001157:Arterial Occlusive Diseases / Q000628:therapy*; D002545:Brain Ischemia / Q000628:therapy*; D002561:Cerebrovascular Disorders / Q000628:therapy*; D003131:Combined Modality Therapy; D003911:Dextrans / Q000008:administration & dosage; D006801:Humans
D003911:Dextrans